Why the omega-3 piggy should go to market [1]

Nature Biotechnology

Volumn 25, Issue 5, 2007, Pages 505-506

  Kang, Jing X ^a   Leaf, Alexander ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

CARDIOVASCULAR RISK; FOOD AND DRUG ADMINISTRATION; FOOD BIOTECHNOLOGY; FOOD INTAKE; GENETICALLY MODIFIED FOOD; LETTER; LIVESTOCK; PRIORITY JOURNAL; SWINE; TRANSGENIC ANIMAL;

ANIMAL WELFARE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOTECHNOLOGY; CLONING, ORGANISM; COMMERCE; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; MARKETING; RESEARCH; SWINE; UNITED STATES;

EID: 34249712460     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0507-505     Document Type: Letter

References (8)

1. Lai, L. et al. Nat. Biotechnol. 24, 435-436 (2006).
2. Deckelbaum, R.J. & Akabas, S.R. Am. J. Clin. Nutr. 84, 1-2 (2006).
3. Gebauer, S.K. et al. Am. J. Clin. Nutr. 83, 1526s-1535s (2006).
4. Hooper, L. et al. Br. Med. J. 332, 752-760 (2006).
5. Simopoulos, A.P. & Cleland, L.G. (eds.) World Rev. Nutr. Diet. 92, 1-152 (2003).
6. Hudert, C.A. et al. Proc. Nat. Acad. Sci. USA 103, 11276-11281 (2006).
7. Xia, S. et al. Proc. Nat. Acad. Sci. USA. 103, 12499-12504 (2006).
8. Wang, C. et al. Am. J. Clin. Nutr. 84, 5-17 (2006).